文献速递其他结缔组织病

抗磷脂综合征患者的羟氯喹与妊娠结局:系统综述与Meta分析

Hydroxychloroquine and pregnancy outcomes in patients with anti-phospholipid syndrome: a systematic review and meta-analysis.
PubMed 文献 · RMD Open · 2025-08-27

该系统综述与Meta分析检索PubMed和EMBASE(2024年4月),纳入7项观察性研究共750例抗磷脂综合征(APS)孕妇,比较羟氯喹(HCQ)联合标准治疗与单用标准治疗。HCQ组活产合并比例为89.9%,非HCQ组为73.9%;产科并发症在HCQ组为19.3%,非HCQ组为55.0%;HCQ与更高的活产率(OR 2.66)和更低的产科并发症(OR 0.19)相关,妊娠期耐受良好。

要点

  • 7项观察性研究共750例APS孕妇,HCQ组活产合并比例89.9%,非HCQ组73.9%。
  • HCQ组产科并发症合并比例19.3%,非HCQ组55.0%。
  • HCQ与更高活产率(OR 2.66;95%CI 1.44至4.91)及更低产科并发症(OR 0.19;95%CI 0.19至0.39)相关。

核心结论

  • 作者认为,HCQ可能通过提高活产概率和降低产科并发症风险,为妊娠期APS患者带来潜在获益。

研究设计与样本

  • 系统综述与Meta分析,系统检索PubMed和EMBASE数据库(2024年4月),纳入7项观察性研究、共750例患者;研究注册于PROSPERO(CRD42024574097)。

主要发现

  • HCQ组活产合并比例为89.9%(95%CI 76.5%至96.0%;I²=81%),非HCQ治疗组为73.9%(95%CI 51.8%至88.2%;I²=81%)。
  • 产科并发症在HCQ组发生于19.3%(95%CI 9.4%至35.4;I²=81%;4项研究),在非HCQ治疗组为55.0%(95%CI 39.4至69.7;I²=79%;4项研究)。
  • 与非HCQ治疗相比,HCQ治疗与更高的活产率(OR 2.66;95%CI 1.44至4.91)和更低的产科并发症(OR 0.19;95%CI 0.19至0.39)相关。
  • 妊娠期HCQ治疗耐受良好。

关键数值与推荐

  • 约20%的APS女性患者在接受阿司匹林和肝素标准治疗时仍出现产科并发症。
  • 主要结局为活产和产科并发症,比较HCQ联合标准治疗与单用标准治疗。

临床怎么用

  • 作者认为,HCQ可能通过提高活产概率和降低产科并发症风险,为妊娠期APS患者带来潜在获益。

局限性

  • 纳入的7项研究均为观察性研究。
  • 活产合并比例的异质性I²=81%,产科并发症合并比例的异质性I²=81%(HCQ组)和I²=79%(非HCQ组)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: About 20% of female patients with anti-phospholipid syndrome (APS) experience obstetric complications despite standard treatment with aspirin and heparin. Treatment with hydroxychloroquine (HCQ) was shown to reduce disease flares during pregnancy in patients with systemic lupus erythematosus and to improve pregnancy outcomes. OBJECTIVES: To evaluate the impact of HCQ on live birth and obstetric complication rates in pregnant women diagnosed with APS. METHODS: We systematically searched PubMed and EMBASE databases in April 2024 for original, peer-reviewed studies on HCQ efficacy and safety in APS patients. The main outcomes measured were live births and obstetric complications, comparing HCQ plus standard therapy to standard therapy alone. RESULTS: Seven observational studies met our inclusion criteria, comprising a total of 750 patients included in the meta-analysis. The overall pooled proportions of live births in the HCQ group were 89.9% (95% CI 76.5% to 96.0%; I 2=81%) and 73.9% (95% CI 51.8% to 88.2%; I 2=81%) in the non-HCQ-treated group. The overall pooled proportion of obstetric complications occurred in 19.3% (95% CI 9.4% to 35.4; I 2=81%; four studies) of the HCQ group and 55.0% (95% CI 39.4 to 69.7; I 2=79%; four studies) of the non-HCQ treated group. Treatment with HCQ was associated with higher rates of live births (OR 2.66; 95% CI 1.44 to 4.91) and lower obstetric complications (OR 0.19; 95% CI 0.19 to 0.39) compared with non-HCQ treatment. HCQ treatment during pregnancy was well tolerated. CONCLUSIONS: Our findings suggest that HCQ may offer potential benefits to APS patients during pregnancy by increasing the probability of live birth rates and lowering the risk for obstetric complications. PROSPERO REGISTRATION NUMBER: The study was registered with PROSPERO, the prospective international register of systematic reviews (identification number CRD42024574097).

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Berman A, Kenet G, Lubetsky A, et al. Hydroxychloroquine and pregnancy outcomes in patients with anti-phospholipid syndrome: a systematic review and meta-analysis. RMD Open. 2025. PMID: 40866107. doi:10.1136/rmdopen-2025-005825

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。